Gastroenterology

Digestive disease, hepatology, endoscopy and inflammatory bowel disease.

Haemostatic gel fails to prevent delayed bleeding after EMR in PURPLE trial

In a multicentre randomized trial, a haemostatic gel did not lower delayed bleeding after EMR of large flat duodenal and colorectal lesions.

By Dr. A. Nikhil Krishnan, MBBS · Oct 20, 2026 · 5 min read

Gastroenterology·Gut

Capsule Endoscopy and Double-Balloon Enteroscopy Diverge in Mid-Gut Bleeding

Peruvian referral-center data found low overall agreement between capsule endoscopy and double-balloon enteroscopy in mid-gut bleeding, with moderate…

Oct 20, 2026

Gastroenterology·Gut

FIT Screening Adherence Shapes Colorectal Cancer Detection Over Time

Long-term FIT adherence lowered positivity and detection after early rounds, but clinically meaningful colorectal cancer yield persisted in…

Oct 20, 2026

Gastroenterology·Gut

Personalized Nutrition May Refine Care in Obesity, MASLD, and MetS

A narrative review finds personalized nutrition may improve metabolic risk in obesity, MASLD, and metabolic syndrome, but routine…

Oct 20, 2026

Gastroenterology·ACC-PRO

Emvistegrast phase 2 results lift Gilead’s UC oral candidate

Gilead’s once-daily oral α4β7 inhibitor emvistegrast met its phase 2 ulcerative colitis endpoint, with 2027 phase 3 plans…

Oct 20, 2026

Gastroenterology·MedCity

Phantom GI raises $5M for minimally invasive ostomy device

Phantom GI raised $5 million to advance PercStoma, a minimally invasive ostomy device aimed at bowel obstruction patients…

Oct 20, 2026

Gastroenterology·NEJM

Icotrokinra Shows Oral Efficacy in Ulcerative Colitis Phase 2 Trial

An oral interleukin-23 receptor blocker improved week 12 clinical response in ulcerative colitis across all tested doses in…

Oct 19, 2026

Gastroenterology·ACC-PRO

AbbVie Crohn’s combination outperforms Skyrizi in phase 2 trial

AbbVie’s dual-target Crohn’s regimen ABBV-466 beat Skyrizi in phase 2, with higher endoscopic remission and similar serious adverse…

Oct 19, 2026

Gastroenterology·STAT

Gilead IBD drug eliminated symptoms in mid-stage study

Gilead’s oral IBD therapy eliminated symptoms in a mid-stage study, with limited details available from the abstract alone.

Oct 19, 2026

Gastroenterology·NIH

Budesonide MMX in Japanese ulcerative colitis study appears in NLM catalog

NLM catalog entry lists supplemental material for a multicenter retrospective study of budesonide MMX in Japanese patients with…

Oct 19, 2026

Gastroenterology

Digestive disease, hepatology, endoscopy and inflammatory bowel disease.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.